...
首页> 外文期刊>Pfluegers Archiv: European Journal of Physiology >Toll-like receptor 2 mediates vascular contraction and activates RhoA signaling in vascular smooth muscle cells from STZ-induced type 1 diabetic rats
【24h】

Toll-like receptor 2 mediates vascular contraction and activates RhoA signaling in vascular smooth muscle cells from STZ-induced type 1 diabetic rats

机译:Toll样受体2介导STZ诱导的1型糖尿病大鼠血管平滑肌细胞中的血管收缩并激活RhoA信号传导

获取原文
获取原文并翻译 | 示例
           

摘要

Increased vascular smooth muscle cell (VSMC) contraction is an early and critical contributor to the pathogenesis of vascular dysfunction in diabetes; however, knowledge regarding the underlying mechanisms is scarce. Toll-like receptor 2 (TLR2), a well-known component of the innate immunity, is expressed in VSMC and recently has been identified to be systemically activated in diabetes. Whether TLR2 is locally activated in the diabetic blood vessels and have effect on contraction is not known. In the current study, we examined the role of TLR2 in increased vascular contraction in diabetes. Utilizing rat model of type 1 diabetes (induced by streptozotocin (STZ)), we demonstrated that aortas from STZ-diabetic rats exhibit increased expression of TLR2 and its adaptor protein, myeloid differentiation primary response 88 (MyD88), as well as enhanced protein-protein interaction between TLR2 and MyD88, suggesting a TLR2 signaling activation. Blockade of TLR2 in intact aortas using anti-TLR2 antibody attenuated increased vascular contraction in STZ-diabetic rat as assessed by wire myograph. Activation of TLR2 by specific ligand in primary aortic VSMC cultures triggered activation of RhoA which was exacerbated in cells from STZ-diabetic rats than control rats. Activation of RhoA was accompanied by phosphorylation and therefore activation of its downstream targets myosin phosphatase target subunit I and myosin light chain (markers of VSMC contraction). Taken together, these results provide evidence for the role of TLR2 in increased contraction in diabetic blood vessels that involves RhoA signaling. Thus, targeting vascular TLR2 offers a promising drug target to treat vascular dysfunction in diabetes.
机译:血管平滑肌细胞(VSMC)收缩的增加是糖尿病血管功能障碍发病机制的早期和关键因素。但是,关于底层机制的知识却很少。 Toll样受体2(TLR2)是先天免疫的一个众所周知的组成部分,在VSMC中表达,最近已被确定在糖尿病中被全身激活。尚不清楚TLR2是否在糖尿病血管中被局部激活并且对收缩有影响。在当前的研究中,我们检查了TLR2在糖尿病血管收缩中的作用。利用1型糖尿病大鼠模型(由链脲佐菌素(STZ)诱导),我们证明了来自STZ糖尿病大鼠的主动脉显示TLR2及其衔接蛋白的表达增加,髓样分化初级反应88(MyD88)以及增强的蛋白- TLR2和MyD88之间的蛋白相互作用,提示TLR2信号激活。通过线肌成像仪评估,使用抗TLR2抗体阻断完整主动脉中的TLR2可以减轻STZ糖尿病大鼠血管收缩的增加。主动脉VSMC培养物中特定配体对TLR2的激活触发了RhoA的激活,在STZ糖尿病大鼠的细胞中,RhoA的表达比对照大鼠加剧。 RhoA的活化伴随着磷酸化,因此其下游靶标肌球蛋白磷酸酶靶标亚基I和肌球蛋白轻链也被激活(VSMC收缩的标志)。综上所述,这些结果提供了TLR2在涉及RhoA信号传导的糖尿病血管收缩增加中的作用的证据。因此,靶向血管TLR2为治疗糖尿病中的血管功能障碍提供了有希望的药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号